{"version":"1.0","type":"link","title":"Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with  V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to / inhibition.","author_name":"Zhao W 외","author_url":"https://prs-insight.online/author/Zhao%20W","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97113","thumbnail_width":1200,"thumbnail_height":630}